MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere, the Dow ...

Mucinex maker Reckitt Beckiser’s new “simpler and more effective organization” won’t include 190 New Jersey workers. | ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Morgan Stanley lowered the firm’s price target on Organon (OGN) to $15 from $16 and keeps an Equal Weight rating on the shares. The firm ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

In mid-February, Organon pleasantly surprised me with its financial results for the fourth quarter of 2024. So, sales of Hadlima, a biosimilar to Humira, amounted to $44 million in the last three ...